Skip to main content
TB

Transformative Biotech, LLC

Transformative Biotech develops direct-to-PCR technologies that enable rapid and accurate molecular testing for infectious diseases and cancer using extraction-free methods. This approach allows for the collection of various sample types, such as nasal swabs and saliva, facilitating point-of-care diagnostics and multiplex pathogen detection.

Boulder, United StatesFounded 2023350+ followers
Updated 4 months ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Problem

Traditional molecular diagnostic testing for infectious diseases and cancer often requires complex and time-consuming nucleic acid extraction steps. These extraction processes add significant costs, require specialized equipment, and can be a bottleneck in high-throughput testing environments, especially in point-of-care settings.

Solution

Transformative Biotech develops direct-to-PCR technologies that eliminate the need for nucleic acid extraction, enabling rapid and cost-effective molecular testing. Their approach utilizes a proprietary collection and transport buffer that stabilizes various sample types, such as nasal swabs and saliva, allowing for direct amplification and detection of target pathogens or cancer markers. This streamlined workflow reduces processing time, minimizes lab expenses, and simplifies molecular diagnostics, making it suitable for point-of-care applications and high-throughput screening. The technology facilitates multiplex pathogen detection and viral load determination, empowering physicians to make more informed treatment decisions.

Target Audience

The primary target audience includes diagnostic laboratories, hospitals, point-of-care testing facilities, and commercialization partners seeking to deploy rapid and cost-effective molecular diagnostic solutions for infectious diseases and cancer.

Features

  • Direct-to-PCR testing without nucleic acid extraction, reducing time and costs
  • Proprietary collection and transport buffer for stabilization of viral and bacterial samples
  • Compatibility with various sample types, including nasal swabs and saliva
  • Streamlined workflow suitable for high-throughput and point-of-care settings
  • Multiplex capability for simultaneous detection of multiple pathogens in a single sample
  • Viral load determination for effective patient management
This profile is AI-generated and may contain inaccuracies.